Clinical Trials

Enrolling Trials

1-10  of  140
4941L, National Wilms Tumor Late Effects Study
McManus, Michael J
Late Effects - Wilms
Child
The objectives of the study are to determine the incidence of life-threatening medical conditions in survivors of Wilms tumor, specifically a) congestive heart failure; b) second malignant neoplasms (SMNs); c) renal failure, and d) pulmonary fibrosis and interstitial lung disease. To relate the risks of these events to the type and amount of radiation and chemotherapy received. To determine mortality rates in former Wilms tumor patients and to compare these with age, calendar period, and sex-specific national population rates. To determine the risks of serious pregnancy complications and other adverse reproductive events in survivors of Wilms tumor, and to correlate their occurrence with the type and amount of radiation and chemotherapy received in childhood. To determine the rates and natality in former Wilms tumor patients and to compare these with national statistics and determne congenital anomalies in offspring. To determine the frequency of Wilms tumor and other cancers in the children and other family members of Wilms tumor patients. Specifically, a) to estimate the recurrence risk in siblings and offspring; and b) to identify familial cancer syndromes that may involve Wilms tumor patients. To serve as a case-finding resource, identifying the most informative subgroups ofWilms tumor patients for use by a) molecular biologists studying mutations in identified or prospective Wilms tumor genes including genes fomilial Wilms tumor; and b) epidemiologists studying parental occupational exposures and other environmental risk factors.
Carpenter, Bonnie M
(715) 389-3639
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subject 2-17 Years of Age
Belongia, Edward A
Infectious Disease - Other
Vaccine - Other
Child
This study sponsored by MedImmune aims to assess the effectiveness of the quadrivalent live-attenuated influenza vaccine (QLAIV) in children 2-17 years old when compared to the standard trivalent inactivated influenza vaccine (TIV) and to receiving no vaccine at all. The study will enroll children 2-17 years old with febrile acute respiratory illness who seek care in outpatient settings during influenza seasons starting in fall 2013 and ending after the 2017 influenza season. The vaccine was licensed by the FDA based on studies showing the vaccine generates adequate antibody levels.
Strey, Sandra K
(715) 389-4030
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody with an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
Chow, Brian
Infectious Disease - Other
Child
MEDI8897 is an experimental medications used to protect infants against Respiratory Syncytial Virus (RSV), which causes viral bronchiolitis and pneumonia. This is a major cause of hospitalization in children. It is expected that one dose of MEDI8897 can be given one to provide protection against RSV for the entire 5 months of RSV season. This study is being carried out to evaluate the safety and tolerability of MEDI8897 in healthy preterm infants compared with placebo (a substance that looks like the study drug but it does not contain active ingredient.). The study will also measure medication levels of MEDI8897 at different dosages.
Johnson, Tara L
(715) 389-3509
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection
Hall, Matthew C
Infectious Disease - Other
Adult
This study is to evaluate the antiviral effect, pharmacokinetics, safety, and tolerability of presatovir in respiratory syncytial virus (RSV) positive adults who have been hospitalized with acute respiratory infectious symptoms. Participants will receive 1 dose of presatovir and followed for 28 days postdose. Nasal swabs will be collected at each study visit (excluding Day 28) and assayed for change in viral load as the primary endpoint.
Freeman, Sandra K
(715) 387-9059
St. Josephs Hospital - Marshfield
611 Saint Joseph Ave
Marshfield, WI  54449
A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT Syndrome Type 3
Anderson, Kelley P
Cardiology
Adult
This study will evaluate the effect of eleclazine on shortening of the corrected QT interval (QTc), safety, and tolerability in adults with type 3 long QT syndrome (LQT3). During the single-blind treatment period (24 weeks), participants will receive eleclazine and/or eleclazine placebo. Following the single-blind treatment period, participants who have not permanently discontinued study drug will be eligible, at the discretion of the investigator, to continue receiving eleclazine during an open-label extension phase.
Larson, Lisa D
(715) 389-5738
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
A Phase II Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Immunogenicity and Safety of Respiratory Syncytial Virus (RSV) F Vaccine Healthy Elderly Subjects and to Estimate the Incidence Rate of Medically-attended RSV Disease in Vaccine and Placebo Recipients.
Belongia, Edward A
Infectious Disease - Other
Vaccine - Other
Adult
The goal of this study is to learn more about how well people's bodies tolerate a dose of the RSV vaccine, to study the immune response to RSV vaccine in older adults, to find out how often people 60 years old and older get illnesses caused by respiratory viruses over a winter season, whether RSV vaccine has an effect that can be measured, and to find out how well flu shots and the RSV vaccine cause antibodies to be made when they are given together, as compared to when each is given alone. This information will help scientists to know more about the burden of illness caused by respiratory viruses and in developing a widely available vaccine to prevent RSV illness.
Strey, Sandra K
(715) 389-4030
Marshfield Clinic Research Foundation
1000 N Oak
Marshfield, WI  54449
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-trans Retinoic Acid
McManus, Michael J
Blood - Other
Child
This phase III trial studies tretinoin and arsenic trioxide in treating patients with newly diagnosed acute promyelocytic leukemia. Standard treatment for acute promyelocytic leukemia involves high doses of a common class of chemotherapy drugs called anthracyclines, which are known to cause long-term side effects, especially to the heart. Tretinoin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Arsenic trioxide may stop the growth of cancer cells by either killing the cells, by stopping them from dividing, or by stopping them from spreading. Completely removing or reducing the amount of anthracycline chemotherapy and giving tretinoin together with arsenic trioxide may be an effective treatment for acute promyelocytic leukemia and may reduce some of the long-term side effects.
Carpenter, Bonnie M
(715) 389-3639
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)
Naqvi, Sm Bilal H
Lung - Lung
Adult
This randomized phase II/III trial studies how well afatinib dimaleate with cetuximab works and compares it with afatinib dimaleate alone in treating patients with newly diagnosed stage IV or recurrent (has come back), epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer. Afatinib dimaleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways by targeting certain cells. It is not yet known whether afatinib dimaleate is more effective when given alone or with cetuximab in treating patients with non-small cell lung cancer.
Bulgrin, Angela M
(715) 221-7261
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Ladysmith Center
906 College Ave W
Ladysmith, WI  54848
Lakeview Medical Center
1700 West Stout Street
Rice Lake, WI  54868
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI  54481
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI  54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Wernberg, Jessica A
Breast - Breast
Adult
This randomized phase III trial studies lymph node dissection and radiation therapy to see how well it works compared to radiation therapy alone in treating patients with breast cancer previously treated with chemotherapy and surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known if radiation therapy alone is as effective as lymph node dissection and radiation therapy together.
Revels, Cheryl M
(715) 389-4177
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI  54476
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI  54868
Sacred Heart Hospital (Eau Claire)
900 W Clairemont Ave
Eau Claire, WI  54701
St. Josephs Hospital - Marshfield
611 Saint Joseph Ave
Marshfield, WI  54449
St. Michaels Hospital
900 Illinois Ave
Stevens Point, WI  54481
A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Fagbemi, Seth O
Skin
Adult
This randomized phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as v-raf murine sarcoma viral oncogene homolog B V600 (BRAFV600) and cannot be removed by surgery. Ipilimumab and nivolumab may block tumor growth by targeting certain cells. Dabrafenib and trametinib may block tumor growth by targeting the BRAFV600 gene. It is not yet known whether treating patients with ipilimumab and nivolumab followed by dabrafenib and trametinib is more effective than treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab.
Strand, Arika P
(715) 389-7543
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Lakeview Medical Center
1700 West Stout Street
Rice Lake, WI  54868
Marshfield Clinic At James Beck Cancer Center
2251 NORTH SHORE DR
RHINELANDER, WI  54501
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI  54481
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI  54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI  54868
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494